Patents by Inventor Marcus E. Carr
Marcus E. Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11167058Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.Type: GrantFiled: February 15, 2006Date of Patent: November 9, 2021Assignee: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
-
Patent number: 9821084Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.Type: GrantFiled: June 10, 2010Date of Patent: November 21, 2017Assignee: Virginia Commonwealth UniversityInventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
-
Publication number: 20130310779Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.Type: ApplicationFiled: July 26, 2013Publication date: November 21, 2013Applicant: Virginia Commonwealth UniversityInventors: Gary Wnek, Marcus E. Carr, JR., Gary Bowlin, Kelman I. Cohen, Kevin R. Ward, Wayne Barbee, Rao Ivatury
-
Patent number: 8586345Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: GrantFiled: March 21, 2011Date of Patent: November 19, 2013Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Patent number: 8497408Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.Type: GrantFiled: September 14, 2007Date of Patent: July 30, 2013Assignee: Virginia Commonwealth UniversityInventors: Gary Wnek, Marcus E. Carr, Jr., Gary Bowlin, Kelman I. Cohen, Kevin R. Ward, Wayne Barbee, Rao Ivatury
-
Publication number: 20120219612Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
-
Publication number: 20110288026Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: ApplicationFiled: March 21, 2011Publication date: November 24, 2011Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Publication number: 20100310658Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrite to form the tissues and organs.Type: ApplicationFiled: June 8, 2010Publication date: December 9, 2010Inventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, JR.
-
Publication number: 20100291058Abstract: The present invention relates to sealants for skin and other tissues. The sealants include an electroprocessed material. The sealants may contain more than one electroprocessed materials and may contain additional substances. The invention further relates to methods of making and using such sealants.Type: ApplicationFiled: April 12, 2010Publication date: November 18, 2010Applicants: Virginia Commonwealth University, Nanomatrix, Inc.Inventors: Gary L. Bowlin, David G. Simpson, Gary E. Wnek, Marcus E. Carr, JR., Peter J. Stevens, Gary Cadd, I. Kelman Cohen
-
Publication number: 20100292624Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.Type: ApplicationFiled: June 10, 2010Publication date: November 18, 2010Inventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
-
Patent number: 7759082Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrate to form the tissues and organs.Type: GrantFiled: January 26, 2004Date of Patent: July 20, 2010Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, Jr.
-
Patent number: 7615373Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: GrantFiled: May 28, 2003Date of Patent: November 10, 2009Assignees: Virginia Commonwealth University Intellectual Property Foundation, Organogenesis, Inc.Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Publication number: 20090155342Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.Type: ApplicationFiled: February 15, 2006Publication date: June 18, 2009Applicant: Virginia Commonwealth UniversityInventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
-
Patent number: 7468067Abstract: Provided is a tourniquet having two opposing and pivotally movable plates. The plates comprise a clamp that pinches an elastomeric cord. The plates are pivotally biased together by a spring. The cord is attached to a back end of the clamp. A free end of the cord is squeezed by the plates such that a loop of cord is provided. The cord can be pulled from the clamp to reduce the size of the loop. The clamp comprises a safety lock that prevents movement of the plates and slipping of the cord. The safety lock can comprise a button disposed between the plates in the back end of the clamp, preventing the plates from moving together in the back portion, and therefore from moving apart in a front portion that grips the cord. Also, the tourniquet clamp can comprise a dual-sided press connector mechanism for fast release of tourniquet tension.Type: GrantFiled: July 29, 2005Date of Patent: December 23, 2008Assignees: Virginia Commonwealth University, Biotrack, LLCInventors: Mark Licata, Kevin R. Ward, Marcus E. Carr, Jr.
-
Patent number: 7192726Abstract: Platelet contractile force and/or clot elastic modulus measurements are used to identify patients at risk for atherosclerosis or for bleeding during surgical procedures or other applications. Measurements which are elevated are indicative of atherosclerosis, and measurements which are reduced are indicative of a bleeding risk.Type: GrantFiled: August 11, 2000Date of Patent: March 20, 2007Assignee: Hemodyne, Inc.Inventors: Marcus E. Carr, Jr., Ashok Krischnaswami, Erika Martin
-
Publication number: 20040229333Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrate to form the tissues and organs.Type: ApplicationFiled: January 26, 2004Publication date: November 18, 2004Inventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr
-
Patent number: 6787357Abstract: The invention is directed to use of fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or “organ-like” tissue. A preferred embodiment is a plasma-derived fibrin matrix containing cells.Type: GrantFiled: October 5, 2001Date of Patent: September 7, 2004Assignee: Virginia Commonwealth UniversityInventors: Gary L. Bowlin, Gary Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, Helen Fillmore
-
Publication number: 20040037813Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: ApplicationFiled: May 28, 2003Publication date: February 26, 2004Inventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Publication number: 20040013715Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.Type: ApplicationFiled: August 13, 2003Publication date: January 22, 2004Inventors: Gary Wnek, Marcus E Carr, Gary Bowlin, Kelman I Cohen, Kevin R Ward, Wayne Barbee, Rao Ivatury
-
Patent number: 6573104Abstract: Blood clot analysis instrumentation used to evaluate platelet function and clot structure by monitoring force development during clot retraction or upon application of a known amount of force can have a calibration check automatically performed by using a top member with a known amount of mass which is detachable from the instrumentation, and preferably is a disposable component. The calibration check is performed by monitoring force or displacement on a holding member with and without the top member attached. If the difference measured is within a preferred tolerance range, then the instrumentation can be deemed to be within the specifications deemed best suited for the instrument. The top member may also be modified to allow for mixing reagents with the clot, thereby avoiding the need to pre-mix blood with reagents before measurement.Type: GrantFiled: May 10, 2001Date of Patent: June 3, 2003Assignee: Hemodyne, IncorporatedInventors: Marcus E. Carr, Jr., Mark Licata